Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 23, 2006

BrainCells and Organon Collaborate on CNS Drugs

  • BrainCells and Organon will collaborate in the discovery and development of drugs for the treatment of central nervous system disorders.

    BrainCells will use its technology in the area of neurogenesis to identify neuroscience applications for compounds formerly in the Organon clinical-stage pipeline. When BrainCells determines the therapeutic utility for a drug candidate, the companies will work together to develop and reposition the drug for its new use.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »